This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
This overview highlights the metrics that distinguish index and mutual funds, including costs, risk, and historical performance for informed choices.
25,005 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
The U.S. SEC has ended its enforcement action against ConsenSys over MetaMask Swaps and Staking, with no penalties an...
Perplexity’s decision to base its AI tooling on Nvidia’s Vera CPUs over AMD’s x86 chips signals a major shift in the ...
A real-world tech-support scam drained a couple’s life savings before authorities stopped the final transfer. This in...
REX Shares unveils a broadened ETF lineup centered on income, leverage, crypto, and thematic strategies, aiming to me...
A Silicon Valley veteran-turned-policy architect leads a rapid, AI-first shift in U.S. defense strategy, intensifying...
Costco’s stock chart sees a rare bullish cross just ahead of its quarterly report, a signal traders are watching as e...
XRP's leverage and open interest have tumbled, but ETF funds and Ripple's expansion keep money in the ecosystem. Trad...
Cardano’s ADA has traded in a tight range around $0.29-$0.30 for 45 days. A sustained move above $0.30 with higher vo...
Nasdaq and Talos unveil an industry-scale integration aimed at freeing $35 billion in trapped collateral, linking ris...
Bitcoin extended its negative funding run, marking the longest streak in years. Analysts warn of rising short-squeeze...
A Southern California mayor has agreed to plead guilty to helping a foreign government, stepping down as federal inve...